Researchers from the various research organizations in the United States have developed a new experimental vaccine that could stimulate the body’s immune system enough to stop the spread of the human immunodeficiency virus or HIV.
In the various studies researchers have discovered a way to accelerate the defense system of the body in order to prepare it to block the HIV infection.
Scientist have long used a dead or inactive form of microbe to generate the production of antibodies, but this process cannot be applied to HIV research as native proteins of the viral strain are not effective in triggering an appropriate immune system.
The HIV is able to bypass detection by the immune system and can mutate quickly into new strains. This limitation has caused scientists to theorize that, for a successful AIDS vaccine to work, it requires proteins known as immunogens to help the body to produce antibodies that can neutralize HIV. The process involves having the person be exposed to the same immunogen several times.
In the studies, the researchers testifies the effects of one such immunogen known as eOD-GT8 60mer. This protein nanoparticle is created to bind and activate the necessary B cells to fight HIV infection.
This immogen was developed at Schief’s laboratory and it was tested on mice engineered to produce antibiotics similar to those of the human body.
They have used a technique called as B cell sorting to show how an eOD-GT8 60mer immunization was able to trigger the production of antibody precursors that contains traits needed to recognize and block the spread of HIV. This result suggests that the immunogen can potentially be sued for the initial stage of immunizations that will target the HIV infection.
eOD-GT8 60mer vaccine worked well in priming the body of the mouse model to fight HIV.
Scheif said that protein was able to trigger an appropriate immune system similar to the first test.
A concurrent research also showed that eOD-GT8 60mer immunogen launched the immune system of rabbit and primate models.
Researchers are now conducting further studies on other immunogens that could produce similar effects as the eOD-GT8 60mer protein.